Dellann Elliott Mydland on Testing Brain Tumor Tissue

A brain tumor diagnosis can be daunting. Nurses are on the front lines connecting patients to available resources and walking them through the best treatment options.

Jacki Garcia, RN, BSN, CNRN; and Kristin Hendrickson, BA, RN, discuss phase 0 trials and how they can help expedite the research process for brain cancer therapies.

Treatment with the third-generation CAR T-cell agent GD2-CART01 was safe and feasible for patients aged 1 to 25 years with relapsed or refractory high-risk neuroblastoma.

Single-agent adagrasib demonstrated a manageable safety profile and meaningful clinical activity in patients with KRAS G12C–mutated solid tumors.

Vorasidenib met its prespecified progression-free survival endpoint in the phase 3 INDIGO trial.

Among 71 patients with neuroblastoma, 48.6% achieved an objective response and 29% achieved a complete response with a 4-drug combination.